Sangamo Therapeutics Inc (SGMO)
0.5088
+0.02
(+4.84%)
USD |
NASDAQ |
Apr 19, 14:47
Sangamo Therapeutics Cash from Financing (TTM): 14.59M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 14.59M |
September 30, 2023 | 33.96M |
June 30, 2023 | 77.87M |
March 31, 2023 | 94.23M |
December 31, 2022 | 84.66M |
September 30, 2022 | 67.24M |
June 30, 2022 | 28.91M |
March 31, 2022 | 16.06M |
December 31, 2021 | 32.86M |
September 30, 2021 | 37.66M |
June 30, 2021 | 33.79M |
March 31, 2021 | 167.93M |
December 31, 2020 | 153.10M |
September 30, 2020 | 147.40M |
June 30, 2020 | 146.49M |
March 31, 2020 | 142.22M |
December 31, 2019 | 142.03M |
September 30, 2019 | 142.38M |
June 30, 2019 | 142.83M |
March 31, 2019 | 221.34M |
December 31, 2018 | 231.71M |
September 30, 2018 | 242.45M |
June 30, 2018 | 244.09M |
March 31, 2018 | 104.63M |
December 31, 2017 | 97.49M |
Date | Value |
---|---|
September 30, 2017 | 84.76M |
June 30, 2017 | 82.55M |
March 31, 2017 | 3.596M |
December 31, 2016 | 0.337M |
September 30, 2016 | -0.182M |
June 30, 2016 | 14.98M |
March 31, 2016 | 16.72M |
December 31, 2015 | 19.71M |
September 30, 2015 | 18.51M |
June 30, 2015 | 3.932M |
March 31, 2015 | 3.977M |
December 31, 2014 | 102.18M |
September 30, 2014 | 104.80M |
June 30, 2014 | 175.11M |
March 31, 2014 | 175.23M |
December 31, 2013 | 76.11M |
September 30, 2013 | 76.26M |
June 30, 2013 | 5.309M |
March 31, 2013 | 3.815M |
December 31, 2012 | 1.676M |
September 30, 2012 | 1.253M |
June 30, 2012 | 0.79M |
March 31, 2012 | 51.14M |
December 31, 2011 | 51.88M |
September 30, 2011 | 52.18M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
14.59M
Minimum
Dec 2023
167.93M
Maximum
Mar 2021
89.80M
Average
84.66M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 0.785M |
Protalix BioTherapeutics Inc | 24.67M |
Electromed Inc | -0.128M |
Armata Pharmaceuticals Inc | 53.99M |